Exelixis Management
Management criteria checks 3/4
Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 14.42 years. total yearly compensation is $16.42M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth $53.42M. The average tenure of the management team and the board of directors is 8.6 years and 7.5 years respectively.
Key information
Mike Morrissey
Chief executive officer
US$16.4m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 14.4yrs |
| CEO ownership | 0.6% |
| Management average tenure | 8.6yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story
Oct 31
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching
Oct 26Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
Sep 02Exelixis Comes Up Aces
Aug 08If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$467m |
| Jun 30 2024 | n/a | n/a | US$350m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | n/a | n/a | US$208m |
| Sep 30 2023 | n/a | n/a | US$92m |
| Jun 30 2023 | n/a | n/a | US$164m |
| Mar 31 2023 | n/a | n/a | US$154m |
| Dec 31 2022 | US$17m | US$1m | US$182m |
| Sep 30 2022 | n/a | n/a | US$308m |
| Jun 30 2022 | n/a | n/a | US$273m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$8m | US$1m | US$231m |
| Sep 30 2021 | n/a | n/a | US$164m |
| Jun 30 2021 | n/a | n/a | US$94m |
| Mar 31 2021 | n/a | n/a | US$65m |
| Dec 31 2020 | n/a | n/a | US$112m |
| Sep 30 2020 | n/a | n/a | US$152m |
| Jun 30 2020 | n/a | n/a | US$282m |
| Mar 31 2020 | n/a | n/a | US$294m |
| Dec 31 2019 | n/a | n/a | US$321m |
| Sep 30 2019 | n/a | n/a | US$612m |
| Jun 30 2019 | n/a | n/a | US$642m |
| Mar 31 2019 | n/a | n/a | US$650m |
| Dec 31 2018 | n/a | n/a | US$690m |
| Sep 30 2018 | n/a | n/a | US$368m |
| Jun 30 2018 | n/a | n/a | US$323m |
| Mar 31 2018 | n/a | n/a | US$253m |
| Dec 31 2017 | n/a | n/a | US$154m |
Compensation vs Market: Mike's total compensation ($USD16.42M) is above average for companies of similar size in the US market ($USD8.00M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Morrissey (63 yo)
14.4yrs
Tenure
US$16,423,307
Compensation
Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 30yrs | US$519.97k | 0.43% $ 41.3m | |
| CEO, President & Director | 14.4yrs | US$16.42m | 0.56% $ 53.4m | |
| Executive VP & CFO | 9.4yrs | US$4.95m | 0.16% $ 15.5m | |
| Executive VP of Discovery and Translational Research & Chief Scientific Officer | 2yrs | US$5.65m | 0.080% $ 7.6m | |
| Executive VP & General Counsel | 10.8yrs | US$4.56m | 0.093% $ 8.8m | |
| Executive VP | 1.3yrs | US$7.38m | 0.011% $ 1.1m | |
| Executive Vice President of Public Affairs & Investor Relations | 8yrs | no data | no data | |
| Senior Vice President of Human Resources | less than a year | no data | no data | |
| Senior Vice President of Drug Safety | 9.7yrs | no data | no data | |
| Senior Vice President of Medical Affairs | 9.3yrs | no data | no data | |
| Executive Vice President of Commercial | 8yrs | US$4.65m | 0.036% $ 3.4m | |
| VP & Head of Business Development | no data | no data | no data |
8.6yrs
Average Tenure
57yo
Average Age
Experienced Management: EXEL's management team is seasoned and experienced (8.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 30yrs | US$519.97k | 0.43% $ 41.3m | |
| CEO, President & Director | 14.4yrs | US$16.42m | 0.56% $ 53.4m | |
| Independent Director | 20.8yrs | US$490.97k | 0.12% $ 11.0m | |
| Independent Director | 20.3yrs | US$482.22k | 0.053% $ 5.0m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 8.3yrs | US$490.92k | 0.00027% $ 25.7k | |
| Independent Director | 6.7yrs | US$488.72k | 0.025% $ 2.4m | |
| Independent Director | 1.6yrs | US$717.44k | 0.0016% $ 151.2k | |
| Independent Director | 1.6yrs | US$716.19k | 0.0016% $ 151.2k |
7.5yrs
Average Tenure
68yo
Average Age
Experienced Board: EXEL's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Exelixis, Inc. is covered by 39 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |